Problem

The early stage products team at a top 5 pharmaceutical company wanted to understand the potential clinical and commercial attractiveness of selected, diverse auto-immune indications

Solution

  • Desk research and one-to-one interviews with KOLs and payers to understand and score the clinical and commercial attractiveness of each opportunity using comprehensive criteria.
  • Leverage proprietary Multi-Variable Analysis (MVA) engine to build weighted assessments for decision making, which included:
    • Burden of disease and level of unmet need in each population
    • The underlying disease causes and the scientific rationale / appeal of MoAs that could address these causes
    • Technical and regulatory feasibility of clinical development
    • Hurdles and required outcomes for new treatments
    • Commercial viability (including patient group size and trends, likely future competitive environment and market access issues)

Outcome

  • Identification and prioritization of the most attractive opportunities, including clusters of diseases / indications and targets / MoAs that could drive opportunity pathways for the auto-immune portfolio
  • Clear direction on the business opportunities and potential development strategies for the auto-immune portfolio